Article citationsMore>>

K. Venken, F. Schuit, L. Van Lommel, K. Tsukamoto, J. J. Kopchick, K. Coschigano, C. Ohlsson, S. Moverare, S. Boonen, R. Bouillon and D. Vanderschueren, “Growth without Growth Hormone Receptor: Estradiol Is a Major Growth Hormone-Independent Regulator of Hepatic IGF-I Synthesis,” Journal of Bone and Mineral Research, Vol. 20, No. 12, 2005, pp. 2138-2149. doi:10.1359/JBMR.050811

has been cited by the following article:

• TITLE: Low Testosterone—An Important Predictor of Low Mineral Bone Density in Young Men—Our Own Experience and a Review of Literature

  AUTHORS: Michael Funaro, Alexander Bolyakov, Elena Gimenez, Michael Herman, Darius A. Paduch

  KEYWORDS: Osteopenia; Osteoporosis; Hypogonadism; Infertility; Sexual Dysfunction

  JOURNAL NAME: Advances in Sexual Medicine, Vol.3 No.3A, August 1, 2013

  ABSTRACT: Urologists and reproductive endocrinologists have become the first contact physicians for young men of reproductive age and have the unique opportunity to positively affect men’s health and quality of life. Growing evidence indicates that a significant proportion of men presenting with infertility or sexual dysfunction are hypogonadal. One hundred ninety nine men were enrolled in our center, and mean total testosterone was = 122, 57%), osteopenia (n = 69, 39%) and osteoporosis (n = 8, 4%). There were no differences in the mean age (p 0.64), height (p 0.99) and weight (p 0.02). Our results indicate that hypogonadism is one of the main risk factors for osteopenia and osteoporosis which can be found in 8% of hypogonadal men younger than 50 years of age. Testosterone replacement therapy may be indicated in most men with hypogonadism and low bone mineral density (BMD); however the benefits of testosterone treatment in eugonadal men are unproven. Selective estradiol and androgen receptor modulators expand our treatment modalities in men of reproductive age when suppression of gonadotropins may interfere with reproductive plans. Early detection of hypogonadism and osteoporosis may lower the risk of hip and vertebral fractures in some men. Further prospective RCTs are needed to prove cost-effectiveness of detection and the best treatment of osteoporosis in hypogonadal men of reproductive age. Urologists have the opportunity to be at the forefront of greater awareness of this clinical problem due to their frequent contact with this population of patients.